CardioVascular BioTherapeutics to Present at the 4th Annual World Health Care Congress.

Panel Discussion will Address New Medical Therapies to Reduce the Cost of Cardiovascular Diseases

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT), today announced that it will host a panel discussion at the 2007 World Health Care Congress on Monday, April 23rd, at 10:00 a.m. The panel, titled "Cardiovascular Diseases - New Medical Therapies to Reduce Cost," will be moderated by Daniel C. Montano, co-founder, co-president and CEO of CVBT. The World Health Care Congress will be held April 22-24 at the Washington Convention Center in Washington, D.C.

As part of the panel discussion, Thomas J. Stegmann, MD, co-founder, co-president and chief medical officer, will give an overview of possible new medical therapies to treat coronary heart disease, peripheral artery disease (PAD), dermal wounds, stroke and chronic back pain. As a cardiac surgeon whose research is focused in the field of neo-angiogenesis and human growth factors, Dr. Stegmann pioneered the angiogenesis procedure upon which CVBT was founded. His clinical studies used a protein therapy to treat certain types of cardiovascular disease, opened a new area of biotechnology and introduced a new potential type of "physiological" treatment for various kinds of atherosclerotic cardiovascular diseases.

In addition, Dr. Joseph Kaufmann, chief medical officer of Sierra Health Services, will speak on the cost of cardiovascular disease and how angiogenesis therapy could reduce the economic burden. Michael Russo, partner at the Bruckner Group, will provide an overview of the macro-medical economic outcomes.

CVBT is developing a technology to administer human Acidic Fibroblast Growth Factor, also known as Fibroblast Growth Factor-1 (FGF-1), to stimulate new blood vessel growth in a process called angiogenesis. FGF-1 is delivered via direct injection into the heart muscle.

"We are honored to be part of this year's World Health Care Congress, and excited to exchange ideas with the industry's premier thought leaders to advance health care quality, access and contain costs," said Daniel Montano. "Over $283 billion is estimated to be spent in 2007 in hospital costs, medical professional services and drug costs to treat cardiovascular disease in the United States according to the American Heart Association. CVBT is committed to bringing to market a cost-effective heart drug candidate that will reduce the suffering and improve the quality of life of individuals affected by this devastating disease."

The 4th Annual World Congress is World Congress' flagship event in which health care, government and corporate leaders formulate solutions to the challenges of health care cost, quality and delivery. The event will convene CEOs and senior executives from the major sectors in health care to determine actionable goals and implementation strategies to demonstrate quality, consumer choice, cost-effectiveness and transparency. The event further provides a forum for thought leaders to engage in debates, present case studies and share best practices from all industry sectors including leading employers, CMS officials, insurers/payers, health system and hospital providers, pharmaceutical and biotech executives, academics, analysts and government officials.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company focused on developing formulations of its active pharmaceutical ingredient Fibroblast Growth Factor-1141(FGF-1141), to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. FGF-1, a protein, facilitates new blood vessel growth, a process called angiogenesis. The Company is developing injectable and topical formulations of FGF-1141 to facilitate angiogenesis in the heart and other tissues and organs. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered surgically in patients with severe coronary heart disease. Additionally, the Company is conducting a Phase I clinical trial for dermal diabetic and venous ulcer healing, and has received authorization from the FDA to begin a Phase I clinical trial in patients with intermittent claudication, a form of PAD.